These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19488079)

  • 41. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
    Kuzawińska O; Lis K; Cessak G; Mirowska-Guzel D; Bałkowiec-Iskra E
    Neurol Neurochir Pol; 2016; 50(6):463-467. PubMed ID: 27553188
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CGRP antagonists: unravelling the role of CGRP in migraine.
    Doods H; Arndt K; Rudolf K; Just S
    Trends Pharmacol Sci; 2007 Nov; 28(11):580-7. PubMed ID: 17963849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CGRP receptor antagonism and migraine therapy.
    Edvinsson L; Warfvinge K
    Curr Protein Pept Sci; 2013 Aug; 14(5):386-92. PubMed ID: 23745702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
    Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
    J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.
    Link AS; Kuris A; Edvinsson L
    J Headache Pain; 2008 Feb; 9(1):5-12. PubMed ID: 18217201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.
    Chaitman BR; Ho AP; Behm MO; Rowe JF; Palcza JS; Laethem T; Heirman I; Panebianco DL; Kobalava Z; Martsevich SY; Free AL; Bittar N; Chrysant SG; Ho TW; Chodakewitz JA; Murphy MG; Blanchard RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):459-66. PubMed ID: 22278333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.
    Hostetler ED; Joshi AD; Sanabria-Bohórquez S; Fan H; Zeng Z; Purcell M; Gantert L; Riffel K; Williams M; O'Malley S; Miller P; Selnick HG; Gallicchio SN; Bell IM; Salvatore CA; Kane SA; Li CC; Hargreaves RJ; de Groot T; Bormans G; Van Hecken A; Derdelinckx I; de Hoon J; Reynders T; Declercq R; De Lepeleire I; Kennedy WP; Blanchard R; Marcantonio EE; Sur C; Cook JJ; Van Laere K; Evelhoch JL
    J Pharmacol Exp Ther; 2013 Nov; 347(2):478-86. PubMed ID: 23975906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Possible site of action of CGRP antagonists in migraine.
    Tfelt-Hansen P; Olesen J
    Cephalalgia; 2011 Apr; 31(6):748-50. PubMed ID: 21383046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A new therapeutic principle for migraine].
    Ashina M; Jensen RH
    Ugeskr Laeger; 2008 Mar; 170(12):1029. PubMed ID: 18397647
    [No Abstract]   [Full Text] [Related]  

  • 50. Management of acute and chronic migraine.
    Coppola G; Schoenen J
    Curr Opin Support Palliat Care; 2012 Jun; 6(2):177-82. PubMed ID: 22406987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
    Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
    Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CGRP - a target for acute therapy in migraine: Clinical data.
    Messina R; Goadsby PJ
    Cephalalgia; 2019 Mar; 39(3):420-427. PubMed ID: 29616830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine.
    Hewitt DJ; Martin V; Lipton RB; Brandes J; Ceesay P; Gottwald R; Schaefer E; Lines C; Ho TW
    Headache; 2011 Apr; 51(4):533-43. PubMed ID: 21457238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eager for better migraine therapies: keep your (telcage)PANTs on.
    Lipton RB; Sandor PS
    Neurology; 2014 Sep; 83(11):954-5. PubMed ID: 25107883
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
    Sinclair SR; Kane SA; Van der Schueren BJ; Xiao A; Willson KJ; Boyle J; de Lepeleire I; Xu Y; Hickey L; Denney WS; Li CC; Palcza J; Vanmolkot FH; Depré M; Van Hecken A; Murphy MG; Ho TW; de Hoon JN
    Br J Clin Pharmacol; 2010 Jan; 69(1):15-22. PubMed ID: 20078608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.
    Depré M; Macleod C; Palcza J; Behm M; de Lepeleire I; Han T; Panebianco D; Smith W; Blanchard R; Chodakewitz J; Murphy M; de Hoon J
    Cephalalgia; 2013 Dec; 33(16):1292-301. PubMed ID: 23798725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapy and prophylaxis of migraine].
    Diener HC; Rabe K
    MMW Fortschr Med; 2012 Apr; 154(7):52-5. PubMed ID: 22558876
    [No Abstract]   [Full Text] [Related]  

  • 58. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current understanding and treatment of headache disorders: five new things.
    Marmura MJ; Silberstein SD
    Neurology; 2011 Feb; 76(7 Suppl 2):S31-6. PubMed ID: 21321349
    [No Abstract]   [Full Text] [Related]  

  • 60. Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding.
    Moore EL; Gingell JJ; Kane SA; Hay DL; Salvatore CA
    Biochem Biophys Res Commun; 2010 Mar; 394(1):141-5. PubMed ID: 20188075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.